# Leap Therapeutics

Leap Therapeutics is an Asset Manager based in Cambridge, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** 47 Thorndike St, Suite B1-1, Cambridge, MA, 02141, United States
- **Assets under management:** Undisclosed
- **Website:** leaptx.com
- **LinkedIn:** https://www.linkedin.com/company/leap-therapeutics

## Regulatory record

- **Reports private funds:** No

## About

Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research.

## Sectors

- Healthcare Services
- Biotechnology

## People

- Douglas Onsi — President & CEO
- Christopher Mirabelli — Chairman of the Board of Directors
- Khing Oei — Director
- Will McEvoy — Director
- James Cavanaugh — Director
- Thomas Dietz — Director
- William Li — Director
- Joseph Loscalzo — Director
- Nissim Mashiach — Director
- Patricia Martin — Director
- Christian Richard — Director
- Richard L. Schilsky — Director

## Questions

### Who runs investment decisions at Leap Therapeutics?

Douglas Onsi serves as President and CEO, responsible for corporate strategy and pipeline development. The board of directors includes members from venture capital and investment firms, providing oversight.

### What is Leap Therapeutics' lead drug candidate?

Sirexatamab (DKN-01) is a humanized monoclonal antibody targeting the DKK1 protein, in clinical development for esophagogastric, gynecologic, and colorectal cancers.

### How does Leap Therapeutics source its drug targets?

Leap in-licenses or internally discovers antibodies against well-validated cancer targets. DKN-01 targets DKK1, FL-301 targets Claudin18.2, and FL-501 targets GDF-15. The company does not disclose specific licensing partners.

### What investment stages does Leap Therapeutics target?

Leap is a clinical-stage biotech developing early-to-mid-phase oncology assets. It invests internal resources in its own pipeline, not external deals.

### Does Leap Therapeutics invest in other companies?

No. Leap focuses entirely on advancing its own drug candidates and does not function as an investment vehicle for external firms.

### Where does Leap Therapeutics' founding wealth come from?

Leap Therapeutics was founded as a venture-backed biotech. Its early investors included HealthCare Ventures, where Chairman Christopher Mirabelli is a managing director. The specific founding wealth origin is not publicly disclosed.

## Related profiles

- [Avid Ratings](https://altss.com/profile/avid-ratings)
- [PetMed Express](https://altss.com/profile/petmed-express)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/leap-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology